insights_auto
Why is 22UA down 6,99%?
Dive Deeperchevron_right
22UA:FRA
BioNTech SE - ADR
€79,80
arrow_downward
-6,99%(-6,00) 1D
13 Okt., 22:00:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€85,45
High
€85,45
Low
€79,75
Mkt. cap
22,36 mjd
Avg. vol.
1,30 k
Volume
3,30 k
52-wk high
€105,50
52-wk low
€68,00
No. of employees
8 k
Open
€85,45
High
€85,45
Low
€79,75
Mkt. cap
22,36 mjd
Avg. vol.
1,30 k
Volume
3,30 k
52-wk high
€105,50
52-wk low
€68,00
No. of employees
8 k
News stories
From web sources and news partners
TradingKey
·
38 minute gelede
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
ad-hoc-news.de
·
1 uur gelede
BioNTech's BNT113 Hangs on Overall Survival as Shares Retreat
GuruFocus
·
5 uur gelede
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR